Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tafinlar-Mekinist dabrafenib trametinib Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation Pending
Truxima Rituximab Cancelled
Kivexa Abacavir/lamivudine HIV infection List in a similar manner to other drugs in class Complete
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
Orencia Abatacept Arthritis, rheumatoid List with clinical criteria and/or conditions Complete
Orencia Abatacept Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Orencia Abatacept Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid List with clinical criteria and/or conditions Complete
Orencia Abatacept Arthritis, Rheumatoid List in a similar manner Complete
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Reimburse with clinical criteria and/or conditions Complete
Verzenio Abemaciclib Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Active
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
Zytiga Abiraterone Withdrawn
Zytiga Abiraterone acetate Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
n/a abiraterone acetate and prednisolone High-risk non-metastatic prostate cancer Reimburse with clinical criteria and/or conditions Complete
N/A abiraterone, prednisone, docetaxel Metastatic castration sensitive prostate cancer (mCSPC) Reimburse Complete
Dysport Therapeutic abobotulinumtoxinA lower limb spasticity Reimburse with clinical criteria and/or conditions Complete
Dysport Therapeutic abobotulinumtoxinA Upper limb spasticity Reimburse with clinical criteria and/or conditions Complete
Dysport Therapeutic abobotulinumtoxinA Cervical dystonia Reimburse with clinical criteria and/or conditions Complete
Cibinqo abrocitinib Atopic dermatitis, moderate to severe Reimburse with clinical criteria and/or conditions Complete
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Reimburse with clinical criteria and/or conditions Complete
Campral Acamprosate calcium Alcohol Abstinence List with clinical criteria and/or conditions Complete
Campral Acamprosate calcium Alcohol Abstinence N/A Complete
Tudorza Genuair Aclidinium bromide Chronic Obstructive Pulmonary Disease List with criteria/condition Complete